SecBot SecBot

PFE drug pipeline

PFIZER INC · 34 rated drugs
$28.89
+0.2% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.5%
1-day, median of 40 events
IV rank
Subscribers
Current print for subscribers
Rated drugs
34
3 bearish · 31 neutral
Phase 3 trials
11
0 with results posted

Upcoming catalysts

8 dated
  1. Dec 2, 2026
    Ritlecitinib higher dose
    Phase 3 primary completion
  2. Dec 8, 2026
    Litfulo
    Phase 2 primary completion
  3. Dec 28, 2026
    Xtandi
    Phase 3 primary completion
  4. Dec 30, 2026
    Vepdegestrant (ARV-471/PF-07850327)
    Phase 3 primary completion
  5. Dec 31, 2026
    Talzenna
    Phase 3 primary completion
  6. Dec 31, 2026
    PF-07104091 monotherapy dose escalation
    Phase 2 primary completion
  7. Jan 18, 2027
    Abrysvo
    Phase 3 primary completion
  8. Jan 29, 2027
    disitamab vedotin
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since mid-2023.

Abrysvo respiratory syncytial virus vaccine (bivalent, recombinant) Updated Nov 3

What to watch

Abrysvo has no upcoming PDUFA dates or pivotal readouts; it is an approved, commercial product. Watch Pfizer's quarterly earnings reports for Abrysvo sales trends, particularly during the fall RSV season (September-January). The key competitive dynamic to monitor is whether Abrysvo can gain market share from GSK's Arexvy following its broader adult label (18-59 at-risk) and whether the GBS warning materially impacts uptake.

Bull case
  • Abrysvo is the only RSV vaccine approved for pregnant individuals to protect infants, giving it a unique market position that competitors GSK (Arexvy) and Moderna (mRESVIA) cannot match.
  • Abrysvo has the broadest adult label of any RSV vaccine, covering adults 18-59 at increased risk, whereas GSK's Arexvy and Moderna's mRESVIA are only approved for ages 50+.
  • Pfizer's Q3 2026 earnings (Nov 3, 2026) beat estimates, and the company raised full-year 2026 guidance, with launched/acquired products (including Abrysvo) growing 32% operationally year-over-year.
Bear case
  • Abrysvo sales declined from $890 million in 2023 (first year) to $755 million in 2024, and Q3 2025 and Q3 2026 both showed year-over-year sales declines amid a tough US vaccine market and narrowed CDC recommendations.
  • GSK's Arexvy dominates the RSV vaccine market with roughly two-thirds market share and $1.5 billion+ in annual sales, significantly outselling Abrysvo.
  • In January 2025, the FDA required a Guillain-Barre syndrome (GBS) warning on Abrysvo's label, which may dampen consumer and physician uptake.
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 trials succeed, a potential FDA filing would likely occur no earlier than 2028, given that the pivotal VESPER-6 monthly maintenance trial only opened enrollment in June 2026 and obesity trials typically run 12-18 months for primary completion.

berobenatide Updated Nov 4

What to watch

The next catalysts are Phase 3 enrollment updates and any interim data from the VESPER-4, VESPER-5, or VESPER-6 trials, but no hard binary readout or PDUFA date is scheduled within the next 12 months. Positive Phase 3 data would validate the monthly-dosing thesis and could open a large market; negative data (efficacy miss or unexpected safety) would damage Pfizer's obesity strategy and the $10B Metsera acquisition thesis.

Bull case
  • First-in-class monthly dosing: berobenatide is the only GLP-1 RA in development designed for once-monthly maintenance, a significant convenience advantage over weekly injections that could drive adherence and market share.
  • Robust Phase 2b data: VESPER-1 showed ~16% non-placebo-adjusted weight loss at 32 weeks with no plateau, and VESPER-3 demonstrated weight loss was maintained when switching from weekly to monthly dosing.
  • Massive market opportunity: the global obesity drug market is projected to reach $190 billion by 2035, and Pfizer is committing heavily with 10+ Phase 3 studies in 2026 across obesity and comorbidities like sleep apnea and knee osteoarthritis.
Bear case
  • Intense competition: Novo Nordisk's semaglutide (Wegovy/Ozempic) and Eli Lilly's tirzepatide (Zepbound/Mounjaro) already dominate the GLP-1 obesity market, which surpassed $132 billion globally in 2026. Berobenatide's 12.3% placebo-adjusted weight loss trails tirzepatide's ~15-16% in head-to-head comparisons.
  • Phase 3 is just beginning: the pivotal VESPER-6 monthly maintenance trial only opened enrollment in June 2026, and results are likely 12-18 months away. Phase 3 failure or a safety signal would write off Pfizer's $10B Metsera acquisition.
  • GI tolerability: nausea (~38%) and vomiting (~23.3%) rates in Phase 2b were similar to Wegovy, which could limit adherence despite the convenience of monthly dosing.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since August 2023 under accelerated approval for 4th-line-plus relapsed/refractory multiple myeloma. Pfizer plans to submit the MagnetisMM-32 data to global health authorities to seek label expansion into earlier treatment lines, but no specific regulatory filing or PDUFA date has been announced.

Elrexfio elranatamab-bcmm Updated Nov 4

What to watch

Watch for Pfizer's regulatory submission of the MagnetisMM-32 data to the FDA, which would trigger a PDUFA clock for label expansion into earlier-line multiple myeloma. Also monitor the MagnetisMM-7 readout in newly diagnosed post-transplant patients. The key question is whether Elrexfio can carve out meaningful market share against J&J's entrenched Tecvayli franchise as it moves into earlier treatment lines.

Bull case
  • Two positive Phase 3 trials in 2026 (MagnetisMM-5 and MagnetisMM-32) provide a strong evidence base for label expansion into earlier lines of therapy, which could significantly expand the addressable patient population.
  • First off-the-shelf, fixed-dose, subcutaneous BCMA-directed agent with every-other-week or every-4-week maintenance dosing, offering convenience advantages over infused CAR-T therapies.
  • Sales growing 17% year-over-year to $169M in H1 2026, with potential acceleration if label expands to earlier treatment lines.
Bear case
  • Intense competition in the BCMA space from J&J's Tecvayli (teclistamab) and Talvey (talquetamab), Regeneron's Lynozyfic (linvoseltamab), and CAR-T therapies Carvykti and Abecma, all targeting overlapping patient populations.
  • Elrexfio's commercial uptake has been modest (H1 2026 sales of $169M) nearly three years after launch, suggesting slow physician adoption versus competitors.
  • The drug carries a boxed warning for cytokine release syndrome and neurologic toxicity, which can limit its use in community settings.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2015; the latest label expansion was approved June 24, 2026.

Ibrance palbociclib Updated Nov 3

What to watch

Ibrance has no upcoming PDUFA or pivotal readout in the next 12 months; the next major event is the March 2027 patent expiration, which will open the door to generic competition. Watch for Pfizer's Q4 2026 earnings (late January 2027) for the first full-quarter sales data after the June 2026 label expansion, and for any settlement or litigation updates on generic challengers.

Bull case
  • June 2026 FDA approval for HR+/HER2+ metastatic breast cancer maintenance (based on PATINA Phase 3 trial showing 44.3 vs 29.1 months median PFS) expands the addressable patient population and makes Ibrance the only CDK4/6 inhibitor approved across all HER2 statuses in HR+ disease.
  • Still a blockbuster generating ~$4.1B in 2025 sales despite competitive pressure, providing substantial cash flow for Pfizer's pipeline and dividend.
  • Pfizer has a next-generation CDK inhibitor, atirmociclib, in Phase 2/3 development that showed a 40% risk reduction in disease progression in the FOURLIGHT-1 trial, offering a potential pipeline successor.
Bear case
  • Core composition-of-matter patent (US RE47,739) expires March 5, 2027, opening the door to generic competition that will erode the ~$4B+ franchise rapidly.
  • Sales have been declining for four consecutive years as rivals Kisqali (Novartis) and Verzenio (Eli Lilly) gain share; NCCN guidelines favor ribociclib as the only Category 1 preferred CDK4/6 in first-line HR+/HER2- disease.
  • Failed in early breast cancer (PALLAS and PENELOPE-B Phase 3 trials), closing off a much larger adjuvant market opportunity.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market. First FDA approval was June 27, 2018 for melanoma; NSCLC label expansion approved October 11, 2023.

Mektovi binimetinib Updated Nov 4

What to watch

Mektovi has no pending PDUFA date or pivotal readout; the next meaningful event would be any future label expansion data (e.g., the ongoing Phase 2 pediatric craniopharyngioma trial), but that is years from a decision. For Pfizer investors, Mektovi is a steady-growth contributor within a diversified oncology portfolio; the more immediate binary catalysts for PFE stock are elsewhere (e.g., Elrexfio, pipeline readouts).

Bull case
  • Braftovi/Mektovi combined revenue grew 18% year-over-year to $716 million in 2025, and Q2 2026 revenue was $174 million (up 28% YoY), showing strong commercial momentum driven by the NSCLC label expansion.
  • The drug is approved in both the U.S. and EU for melanoma and NSCLC, with recent additional approvals in the UK (NICE, May 2026) and Singapore (November 2026), expanding the addressable market.
  • Pfizer's large commercial infrastructure and oncology salesforce support continued market penetration; Jefferies analysts estimated the regimen could capture 15-20% of the BRAF-mutant NSCLC market, translating to $250-300 million in annual U.S. sales by 2027.
Bear case
  • Generic competition is emerging: Alembic Pharmaceuticals received tentative FDA approval for binimetinib with 180-day marketing exclusivity, and the estimated U.S. market size is $259 million (12 months ending March 2026). Coripharma and Adalvo are also advancing generic versions.
  • Mektovi is always used in combination with Braftovi (encorafenib), so its revenue is tied to the combined brand's market share in BRAF-mutant cancers, a competitive field that includes Novartis' Tafinlar + Mekinist.
  • At roughly $700-800 million in combined Braftovi/Mektovi annual revenue, the product is a small part of Pfizer's $62+ billion total revenue, limiting its individual impact on the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. (since 2020) and multiple international markets.

Nurtec rimegepant Updated Nov 3

What to watch

Nurtec is an approved, commercially established drug with no near-term binary catalyst. Watch quarterly revenue growth trajectory (Q3 2026: $547M, +33% YoY) as a gauge of commercial momentum, and monitor the pediatric Phase 3 programs for potential label expansion, though those are years from completion. Generic entry risk is distant (~2039).

Bull case
  • Nurtec is the first and only migraine medication approved for both acute treatment and prevention in adults, a key differentiating feature versus most competitors.
  • Q3 2026 revenue of $547M grew 33% operationally year-over-year, driven by strong U.S. demand and international launch uptake, showing robust commercial momentum.
  • The global migraine market is large and growing, with the Nurtec ODT market estimated at $2.41B in 2025 and projected to reach $7.21B by 2034.
Bear case
  • Nurtec faces intensifying competition from other oral CGRP antagonists including AbbVie's Qulipta (atogepant) and Ubrelvy (ubrogepant), plus Pfizer's own Zavzpret (zavegepant), which could pressure market share and pricing.
  • As a small part of Pfizer's $63B+ annual revenue, Nurtec's performance has limited ability to move PFE shares meaningfully on its own.
  • Tentative FDA approvals for generic rimegepant (ANDA 219399, ANDA 219440) have been granted, signaling eventual generic entry, though patents are expected to protect the brand until ~2039.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market. First FDA approval was December 2019; latest label expansion July 2026.

Padcev enfortumab vedotin Updated Nov 3

What to watch

Watch for EV-309 (bladder-sparing) Phase 3 data readout, listed on Pfizer's 2026 pipeline catalyst page but still recruiting per ESMO 2026. Any positive readout could support another label expansion. Near-term, track quarterly sales growth trajectory as the July 2026 MIBC label expansion ramps.

Bull case
  • Padcev Q3 2026 revenue hit $720 million, beating the $658M consensus and growing 23% year-over-year, driven by market share gains and the new July 2026 MIBC perioperative label expansion.
  • The July 2026 FDA approval for Padcev + Keytruda in muscle-invasive bladder cancer regardless of cisplatin eligibility opens a large new patient population and is the first platinum-free perioperative regimen.
  • European Commission expanded approval on October 23, 2026 for resectable MIBC, adding international growth runway.
Bear case
  • Pfizer's analyst consensus is mixed: only 13 of 34 analysts rate it Buy/Strong Buy, with a mean price target of $29.26 (2.5% below the current ~$30 stock price), implying limited upside.
  • Padcev faces competition from other ADCs and checkpoint inhibitor combinations in bladder cancer, including the VOLGA trial testing AstraZeneca's Imfinzi with Padcev as a rival regimen.
  • As a single product within Pfizer's $62-64B revenue base, Padcev's $720M quarterly contribution is meaningful but not company-transforming; Pfizer's stock is driven by many factors beyond this one drug.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed. Next-generation 25-valent pediatric vaccine is in Phase 3 (started May 2026); 35-valent adult candidate expected to enter clinical development by end of 2026, with potential approval likely several years away.

Prevnar pneumococcal conjugate vaccine Updated Nov 3

What to watch

Watch for Phase 3 data readouts from Pfizer's 25-valent pediatric pneumococcal vaccine (25vPnC) and the clinical development start of the 35-valent adult candidate, both expected within the next 12-18 months. Near-term, monitor quarterly Prevnar sales trends for market share shifts against Merck's Capvaxive and Vaxcyte's VAX-31, which posted positive Phase 3 results in October 2026.

Bull case
  • Prevnar is the world's highest-revenue vaccine franchise, generating $6.49 billion in 2025, roughly 10% of Pfizer's total revenue (source: PharmaShots Top 20 Vaccines 2026).
  • Prevnar 20 is approved for both adults (June 2021) and pediatrics (April 2023), giving it the broadest approved age indication among pneumococcal conjugate vaccines.
  • Pfizer's next-gen 25-valent pediatric vaccine (25vPnC/PF-07872412) showed strong Phase 2 data at IDWeek 2026 with serotype 3 antibody levels ~15-fold higher than Prevnar 20, and has advanced to Phase 3.
Bear case
  • Prevnar family revenue declined 10% in Q3 2026 year-over-year, driven by lower vaccination rates and market share erosion (per Pfizer's Q3 2026 8-K earnings release).
  • Merck's Capvaxive (PCV21), approved June 2024, covers 21 serotypes and was designed specifically for adults, directly competing with Prevnar 20 in the adult market.
  • Vaxcyte's VAX-31 met all primary endpoints in its pivotal Phase 3 OPUS-1 trial (October 2026), showing non-inferiority to Prevnar 20 on all 20 shared serotypes, threatening Pfizer's long-term franchise.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the US (since 2018 for breast cancer, 2023 for prostate cancer, with the latest label expansion in October 2026). Also approved in the EU for breast cancer and later-line prostate cancer.

Talzenna talazoparib Updated Nov 3

What to watch

The next catalyst for Talzenna is the ongoing label-expansion opportunity in Europe, where the EMA currently only approves the combination for later-line mCRPC, not the earlier mHSPC setting just cleared by the FDA. Any regulatory filing or approval in the EU or additional markets could incrementally support Pfizer's oncology revenue, but given Pfizer's scale, Talzenna alone is unlikely to drive a major stock move.

Bull case
  • Talzenna is the first and only PARP inhibitor approved for metastatic hormone-sensitive prostate cancer (mHSPC), a large addressable patient population, following the October 26, 2026 FDA label expansion based on the positive TALAPRO-3 Phase 3 trial.
  • Talzenna has the strongest PARP trapping potency among approved PARP inhibitors, a potential differentiation advantage in efficacy.
  • The TALAPRO-3 trial demonstrated a 52% reduction in the risk of radiographic progression or death (HR 0.48, p<0.0001), a clinically meaningful result published in the New England Journal of Medicine.
Bear case
  • Talzenna competes in a crowded PARP inhibitor market where AstraZeneca/Merck's Lynparza dominates with an estimated 86% share, limiting Talzenna's market penetration.
  • Patent protection is estimated to expire around October 2031-2032, opening the door to generic competition that will erode revenue.
  • Talzenna is a small part of Pfizer's $63.6B revenue base; even strong sales growth has limited impact on the overall stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since May 2019.

Vyndaqel tafamidis Updated Nov 3

What to watch

Vyndaqel/Vyndamax has no upcoming binary regulatory catalyst; the next key events to watch are quarterly sales trends as competition from BridgeBio's Attruby and Alnylam's Amvuttra intensifies, and any further patent litigation outcomes. For Pfizer, a diversified pharma giant, this drug is one of several growth drivers and not a single-point-of-failure binary.

Bull case
  • Vyndaqel family generated $6.38 billion in 2025 revenue, up 17% year-over-year, making it one of Pfizer's fastest-growing major products.
  • Patent settlements with three generic manufacturers (Dexcel, Hikma, Cipla) extended U.S. exclusivity to June 1, 2031, protecting the franchise from generic erosion through mid-2031.
  • Real-world data published October 2026 showed tafamidis associated with 74% lower all-cause mortality risk in ATTR-CM patients versus untreated patients, reinforcing clinical value.
Bear case
  • Competition is intensifying: BridgeBio's Attruby (acoramidis) launched in November 2024 and a September 2026 real-world study claimed it outperformed Vyndamax. Alnylam's Amvuttra (vutrisiran) also entered the ATTR-CM market.
  • A generic tafamidis received a positive EU regulatory opinion in July 2026, potentially pressuring international pricing and market share outside the U.S.
  • Pfizer discontinued the original Vyndaqel formulation in the U.S. at end of 2025, consolidating the franchise around Vyndamax, which could create transitional friction.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2012. The next inflection point is the US patent expiry in August 2027, which will allow generic competition.

Xtandi enzalutamide Updated Nov 3

What to watch

The next major event for Xtandi is the US composition-of-matter patent expiry in August 2027, which opens the door to generic competition and will pressure revenue. In the nearer term, watch for Pfizer's Q4 2026 earnings (early Feb 2027) for Xtandi sales trends and any update on the talazoparib combo uptake. The ENZARAD trial failure in high-risk localized prostate cancer removes one expansion opportunity.

Bull case
  • Xtandi is a well-established blockbuster with four FDA-approved indications across the prostate cancer treatment continuum, generating ~$6B in global sales (Astellas FY2025).
  • On October 26, 2026, the FDA approved talazoparib (Talzenna) in combination with Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer based on the TALAPRO-3 trial, which showed a 52% reduction in risk of progression or death, extending the franchise's utility.
  • Pfizer's Q3 2026 earnings (reported Nov 3, 2026) beat consensus, and the company raised full-year 2026 guidance, reflecting momentum across its portfolio including oncology.
Bear case
  • Core US composition-of-matter patent expires August 13, 2027, opening the door to generic enzalutamide and a steep revenue decline (Astellas projects a 5.3% drop in FY2026 already).
  • The Phase 3 ENZARAD trial (published October 2026) showed enzalutamide failed to improve metastasis-free survival in high-risk localized prostate cancer (HR 0.88, p=0.34), closing off a potential label expansion.
  • Xtandi faces intense competition from J&J's Erleada (apalutamide), Bayer's Nubeqa (darolutamide), and generic abiraterone, all targeting overlapping prostate cancer indications.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1997.

BeneFIX nonacog alfa Updated Nov 4

What to watch

BeneFIX is a mature, approved product with no upcoming binary catalysts. The key thing to watch is whether biosimilar competition or gene therapy uptake (CSL's Hemgenix) erodes its market share over time, but this is a slow-moving, non-binary dynamic for a drug that is a tiny fraction of Pfizer's $63B+ revenue base.

Bull case
  • BeneFIX is a well-established, FDA-approved therapy with decades of real-world use and a well-characterized safety profile for hemophilia B.
  • Pfizer published positive Phase 3 data for a once-weekly prophylactic dosing regimen (100 IU/kg), which showed a statistically significant reduction in annualized bleeding rate versus on-demand treatment, potentially extending the product's utility.
  • The global hemophilia B market is projected to grow from roughly $3.4 billion in 2025 to $4-6 billion by the early 2030s, providing a stable tailwind for established products.
Bear case
  • Faces intense competition from extended half-life factor IX products (Sanofi's Alprolix, CSL Behring's Idelvion, Novo Nordisk's Rebinyn) that offer less frequent dosing and better bleed protection.
  • Gene therapy competition is emerging: CSL's Hemgenix is approved for hemophilia B, and Pfizer itself discontinued its own gene therapy Beqvez, signaling the standard half-life replacement market may shrink over time.
  • As a standard half-life product first approved in 1997, BeneFIX may face biosimilar competition as patents and exclusivity expire, pressuring pricing and market share.
▼ bearish
Impact
PhaseApproved
Time to marketAlready on the market since 2012. Generic competition entered in June 2026.

Bosulif bosutinib Updated Nov 4

What to watch

Bosulif has no upcoming FDA decision or pivotal readout. The key event already occurred in June 2026 with the launch of generic bosutinib, which will progressively erode brand revenue. For Pfizer investors, the drug is too small to move the stock meaningfully; the more relevant Pfizer catalysts are its broader pipeline readouts and overall revenue trajectory.

Bull case
  • Bosulif remains a standard-of-care option in Ph+ CML with established physician prescribing and patient familiarity.
  • The drug has a broad label covering both newly diagnosed and treatment-resistant CML, supporting continued use despite generic competition.
  • Pfizer's large commercial infrastructure and patient support programs (Pfizer Oncology Together) may help retain some brand-loyal patients and prescribers.
Bear case
  • Generic bosutinib launched in June 2026: Dr. Reddy's launched the 400mg strength with 180-day exclusivity, and Alembic launched 100mg and 500mg generics, directly eroding Bosulif brand revenue.
  • Bosulif 400mg had approximately $253.8M in US sales for the 12 months ended April 2026, and the 100mg/500mg strengths had $291M for the 12 months ended March 2025, representing a significant revenue base now at risk.
  • Global Bosulif sales declined from $645M in 2024 to $611M in 2025 (-5.6%) even before generic entry, indicating pre-existing competitive pressure.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed. Braftovi has been commercially available since its initial FDA approval in June 2018.

Braftovi encorafenib Updated Nov 3

What to watch

Braftovi has no scheduled PDUFA dates or pivotal readouts in the next 12 months; the next catalyst to watch is whether Pfizer pursues a label expansion for the FOLFIRI chemotherapy backbone based on the positive BREAKWATER Cohort 3 data presented at ASCO 2026. For a company the size of Pfizer, Braftovi is a steady commercial contributor but not a standalone stock-moving catalyst.

Bull case
  • Braftovi has three FDA-approved indications (melanoma, NSCLC, mCRC) with strong clinical data, including a 51% reduction in death risk from the Phase 3 BREAKWATER trial.
  • The drug is forecast to command a 42% share of the BRAF inhibitors melanoma market by 2028, per GlobalData.
  • Positive Cohort 3 BREAKWATER data (nearly doubled PFS with FOLFIRI backbone) could support further label expansion and broaden the addressable patient population.
Bear case
  • Braftovi is a small component of Pfizer's overall business (Pfizer's 2026 revenue guidance is $62-64B), so even strong commercial performance has limited impact on the stock.
  • The drug faces competition from other BRAF/MEK inhibitor combinations, including Novartis's Tafinlar + Mekinist and Roche's Zelboraf + Cotellic.
  • No near-term binary catalysts exist for Braftovi, making it a steady but unexciting holding for event-driven biotech investors.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the US (since January 2022) and EU. Patent protection extends to approximately January 2036 per DrugPatentWatch.

Cibinqo abrocitinib Updated Nov 4

What to watch

Cibinqo is an approved, marketed drug with no near-term binary catalysts. Watch for any announcement of a regulatory submission for chronic hand eczema (Phase 2 data was positive in 2026) and for quarterly sales trends within Pfizer's broader earnings reports. The drug's impact on PFE shares will remain modest given Pfizer's size and diversification.

Bull case
  • Cibinqo offers a convenient once-daily oral option in a large and growing atopic dermatitis market, differentiating it from injectable biologics like dupilumab.
  • Positive Phase 2 data for chronic hand eczema (presented at AAD 2026) and a prespecified JADE DARE analysis showing faster hand eczema clearance than dupilumab support a potential label expansion opportunity.
  • Patent protection extends to approximately January 2036, providing a long runway of market exclusivity.
Bear case
  • Cibinqo carries an FDA boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, which limits its use versus biologics like dupilumab that lack such warnings.
  • The atopic dermatitis market is intensely competitive with multiple approved biologics (dupilumab, tralokinumab, lebrikizumab) and oral JAK inhibitors (upadacitinib), pressuring pricing and market share.
  • Cibinqo is a small product within Pfizer's $62B+ revenue base; even strong sales growth would have a negligible impact on the overall stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since August 2021. The latest seasonal strain update (2026-2027 XFG formula) was approved August 27, 2026 and is currently available.

Comirnaty tozinameran Updated Nov 3

What to watch

Comirnaty has no pending PDUFA or pivotal readout; the 2026-2027 seasonal strain update was already approved in August 2026. Watch Q4 2026 vaccination-season sales (management expects the majority of Comirnaty revenue in Q4) and any FDA VRBPAC meetings in mid-2027 that set the next seasonal strain composition. For Pfizer stock, Comirnaty's trajectory is a slow fade; the more important drivers are the non-<|image|>COVID pipeline (oncology, vaccines) and the raised $62-64B full-year revenue guidance.

Bull case
  • Comirnaty remains the leading COVID-19 vaccine by total forecast sales, with a well-established manufacturing and distribution network.
  • The seasonal update process (annual strain changes via sBLA) provides a recurring revenue stream, though declining from pandemic peaks.
  • Pfizer raised full-year 2026 revenue guidance to $62-64 billion on November 3, 2026, with non-COVID growth offsetting COVID declines.
Bear case
  • COVID vaccine demand continues to decline as the pandemic transitions to an endemic seasonal pattern; Pfizer cut its 2026 COVID product revenue forecast to ~$4 billion from an earlier ~$5 billion.
  • Comirnaty faces direct competition from Moderna's Spikevax/mNEXSPIKE and Novavax's Nuvaxovid, all of which received 2026-2027 XFG formula approvals simultaneously.
  • Comirnaty's approved population is narrower than competitors (65+ and high-risk 5-64, vs Moderna's approval down to age 6 months).
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2015 (adults) and 2023 (pediatric).

Cresemba isavuconazonium sulfate Updated Nov 4

What to watch

Cresemba is a mature, approved product with no upcoming binary catalysts. The key event to watch is the next quarterly sales milestone from Pfizer to Basilea, which would signal continued commercial momentum, but this is immaterial to Pfizer's stock. For Basilea (SIX: BSLN), Cresemba royalty and milestone income is the primary value driver.

Bull case
  • Cresemba is the world's largest branded antifungal for invasive fungal infections, with global in-market sales of $817M in the 12 months through June 2026, growing 25% year-over-year.
  • The drug benefits from a growing immunocompromised patient population (cancer, transplant, HIV) driving demand for antifungal therapies.
  • Pediatric approval in December 2023 expanded the addressable market to children as young as one year old, opening a new growth avenue.
Bear case
  • Cresemba is a very small product within Pfizer's $62.6B revenue base and does not appear among Pfizer's top 10 products, making it immaterial to PFE's stock performance.
  • Patent protection is limited: earliest generic entry estimated around December 2030 to June 2031, and the drug has already faced Paragraph IV challenges, creating long-term revenue risk.
  • Pfizer pays mid-teen royalties to Basilea on Cresemba sales, meaning the profit margin for Pfizer is lower than for wholly owned products.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1998.

Enbrel etanercept Updated Nov 4

What to watch

Enbrel is a mature, declining asset for Pfizer with no upcoming binary catalysts. The key events to watch are the 2028-2029 US biosimilar entry window (Eticovo/Erelzi) and continued erosion of international sales, but neither is a near-term catalyst for PFE stock given Enbrel's small contribution to Pfizer's $60B+ revenue base.

Bull case
  • Enbrel remains a clinically important biologic with five FDA-approved indications (rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis) and continues to generate meaningful revenue globally.
  • Amgen's aggressive patent litigation has successfully blocked US biosimilar entry for over a decade, with the latest court rulings pushing the earliest US biosimilar launch to 2028-2029, preserving Enbrel's US market exclusivity for now.
  • For Pfizer, Enbrel is a low-risk, cash-flow-generating legacy product in international markets where it requires no additional R&D investment.
Bear case
  • Enbrel sales are in structural decline: Amgen reported a 37% year-over-year drop in Enbrel sales in Q1 2026, driven by Medicare's Maximum Fair Price of $2,355/month (a 67% cut from list price) that took effect January 1, 2026.
  • Biosimilar competition has already crushed international sales (where Pfizer holds rights), with Pfizer's ex-US Enbrel sales falling from a $3.8B peak in 2014 to much lower levels as European biosimilars launched in 2016.
  • Two FDA-approved etanercept biosimilars (Erelzi and Eticovo) are poised to enter the US market once Amgen's patent protection ends in 2028-2029, which will further pressure pricing and volume.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1995.

Genotropin somatropin Updated Nov 4

What to watch

There are no near-term binary catalysts for Genotropin. Watch for updates on the reusable pen device shortage (expected to last until at least early 2027) and for continued erosion of market share to biosimilar Omnitrope and Pfizer's own once-weekly NGENLA. For Pfizer investors, the drug is a minor, declining contributor within a $63B+ portfolio.

Bull case
  • Genotropin remains a trusted, established brand with multiple FDA-approved indications across pediatric and adult growth disorders, providing a stable base of recurring prescriptions.
  • Pfizer has transitioned to a next-generation product (NGENLA, once-weekly somatrogon) that extends its franchise in the growth hormone market, potentially capturing patients who prefer fewer injections.
  • The global somatropin market is valued at roughly $4.3-$4.8 billion in 2026 and is projected to grow at 5.9-7.5% CAGR through the mid-2030s, providing a rising tide that benefits all players.
Bear case
  • Genotropin is well past patent exclusivity and faces direct biosimilar competition from Sandoz's Omnitrope (approved since 2006), which has already driven down pricing in the category.
  • The reusable pen device for Genotropin has been out of stock since early 2026, with shortages expected until at least early 2027, disrupting patient access and potentially driving switching to competitors.
  • Pfizer's own once-weekly NGENLA (somatrogon) is cannibalizing Genotropin's daily-injection franchise, and Genotropin is not among Pfizer's top 10 products by revenue, making it a minor contributor to the company's $63B+ annual revenue.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US (since October 2024) and EU (since November 2024), with expanded labels in both regions in mid-2026.

Hympavzi marstacimab Updated Nov 4

What to watch

Hympavzi is already approved in both the US and EU for hemophilia A and B with and without inhibitors. No upcoming PDUFA or pivotal readout is scheduled in the next 12 months. The next catalyst to watch would be quarterly sales trajectory and any further label expansion (e.g., younger pediatric patients), but neither is a hard binary event. For a company the size of Pfizer, this drug is unlikely to be a standalone share-price driver.

Bull case
  • First and only anti-TFPI antibody approved for both hemophilia A and B, with or without inhibitors, giving it a broad label that covers both subtypes.
  • Once-weekly subcutaneous injection with a pre-filled auto-injector pen offers convenience versus daily or IV alternatives.
  • Phase 3 BASIS study showed a 93% reduction in bleeds compared to on-demand treatment in patients with inhibitors.
Bear case
  • Faces entrenched competition from Roche's Hemlibra (emicizumab), which generated roughly $4-5 billion in global sales in 2025 and offers less frequent dosing.
  • Other rebalancing agents are entering the market: Sanofi's Qfitlia and Novo Nordisk's Alhemo are gaining physician adoption, per Spherix Global Insights (April 2026).
  • List price of $795,600/year before discounts may face payer pushback and access barriers, especially as multiple rebalancing agents compete for formulary placement.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2016.

Inflectra infliximab-dyyb Updated Nov 4

What to watch

Inflectra is a mature, approved biosimilar with no pending regulatory catalysts. The key events to watch are Pfizer's quarterly biosimilar segment revenue trends and any further market-share shifts in the infliximab biosimilar category, but these are gradual commercial developments, not binary stock-moving catalysts for a company of Pfizer's size.

Bull case
  • Inflectra was the first FDA-approved biosimilar monoclonal antibody and remains a well-established infliximab biosimilar with a 30% US market share.
  • Biosimilars are gaining share in the infliximab market, reaching 51% overall in Q2 2026, with Inflectra holding the largest biosimilar share at 30%.
  • Pfizer's Q3 2026 results beat estimates and the company raised full-year guidance, with non-COVID products including biosimilars driving growth.
Bear case
  • Pfizer voluntarily withdrew Inflectra's EU marketing authorization in May 2026 for commercial reasons, shrinking its addressable market.
  • A Class II FDA recall was initiated in January 2025 after cGMP deviations caused quarantined product to be inadvertently distributed, a manufacturing-quality concern.
  • Pfizer's biosimilar market share dropped from 16.5% to 13.3% between 2023 and 2024, and the infliximab biosimilar space is increasingly crowded with competitors like Renflexis, Avsola, and Flixabi.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2012.

Inlyta axitinib Updated Nov 4

What to watch

Inlyta is a mature, declining-revenue product with no upcoming binary catalysts. Watch for resolution of patent litigation against Sandoz and Alkem, which will determine the timing of generic entry (currently expected 2027-2028). Any settlement or court ruling on the axitinib patents could accelerate or delay generic competition, but even a major patent loss would have a modest impact on Pfizer's overall revenue given Inlyta's ~$923M annual contribution versus Pfizer's $63B+ total revenue.

Bull case
  • Inlyta remains a meaningful contributor to Pfizer's oncology portfolio with ~$923M in 2025 revenue, and it benefits from label expansions into first-line RCC in combination with avelumab (Bavencio) and pembrolizumab (Keytruda).
  • Pfizer is actively defending its patents through litigation, which could delay generic entry beyond current expectations and extend the product's revenue stream.
  • The axitinib market is projected to grow at ~8.5% CAGR through 2033, suggesting continued demand even as generics enter.
Bear case
  • Revenue declined 6% in 2025 to ~$923M, and the downward trend is likely to continue as generic competition approaches.
  • Sandoz has received tentative FDA approval for a generic version of axitinib, and Pfizer's patent lawsuit against Sandoz (filed Nov 2024) creates uncertainty about how long exclusivity will last.
  • Pfizer dropped its patent suit against Alkem in July 2026, though it left the door open to refile, signaling potential weakness in the patent wall.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed for alopecia areata (since June 2023). Vitiligo label expansion is pending regulatory submissions and review, with no set timeline.

Litfulo ritlecitinib Updated Nov 4

What to watch

Watch for Pfizer's vitiligo regulatory submission timing (FDA sNDA and EMA MAA), which could be filed in late 2026 or early 2027. Also monitor the Phase 3 pediatric alopecia areata readout in children ages 6-12, with estimated primary completion in December 2026. Neither catalyst alone is likely to move Pfizer's stock significantly given the company's size and diversification.

Bull case
  • Litfulo is the first and only FDA-approved treatment for severe alopecia areata in patients as young as 12, giving it a unique pediatric/adolescent differentiation versus competitors.
  • Phase 3 TRANQUILLO trials in nonsegmental vitiligo met co-primary endpoints with statistically significant facial and total-body repigmentation at Week 52, supporting planned regulatory filings that could open a large new market.
  • Analysts view ritlecitinib as a potential blockbuster, with some forecasts projecting global net revenues could surpass $2 billion annually by the early 2030s if label expansions succeed.
Bear case
  • Litfulo faces stiff competition in alopecia areata from Eli Lilly's Olumiant (baricitinib) and Sun Pharma's Leqselvi (deuruxolitinib), limiting market share and pricing power.
  • In vitiligo, Litfulo would enter a market where AbbVie's Rinvoq (upadacitinib) was already approved in the EU in July 2026 and Incyte's topical Opzelura (ruxolitinib) is established, potentially narrowing the first-mover advantage.
  • Litfulo carries a boxed warning for serious infections, mortality, malignancy, MACE, and thrombosis, which may limit prescriber uptake versus newer or better-tolerated alternatives.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since November 2018. Full first-line approval granted January 2026.

Lorbrena lorlatinib Updated Nov 3

What to watch

Lorbrena has no near-term binary catalyst. The next event to watch is the Sun Pharma patent litigation (filed Oct 2026 in Delaware), where a ruling could affect generic entry timing. Separately, watch for any label expansion into ROS1-positive NSCLC or pediatric indications. For Pfizer as a whole, Q3 2026 earnings (just reported Nov 3) and the 2027 revenue outlook are far more material than Lorbrena-specific news.

Bull case
  • CROWN trial 7-year data (ASCO 2026) showed 55% of patients alive without progression at 7 years and median PFS not yet reached, arguably the longest PFS ever reported in advanced NSCLC.
  • FDA expanded Lorbrena to full first-line approval in January 2026, broadening the addressable patient population significantly.
  • Pfizer previously guided that Lorbrena could exceed $1B in annual sales by 2030, and the drug is growing double-digits (part of Pfizer's oncology growth story).
Bear case
  • Lorbrena is a small product within Pfizer's $62.6B revenue base; even strong sales growth has negligible impact on the stock.
  • Pfizer faces patent litigation from Sun Pharma (ANDA filed), which could bring generic competition before the compound patent expires in March 2033 if Pfizer loses.
  • The ALK inhibitor class is competitive (alectinib, brigatinib, ensartinib), and pricing pressure could limit Lorbrena's peak sales.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed (FDA full approval granted May 25, 2023; initial EUA December 22, 2021).

nirmatrelvir Updated Oct 30

What to watch

Nirmatrelvir (Paxlovid) is already approved and commercialized by Pfizer; there is no upcoming binary catalyst for this drug. The key overhang was the Enanta patent litigation, which was resolved in Pfizer's favor in June 2026. Watch Pfizer's quarterly earnings for Paxlovid sales trends, which have been declining as COVID-19 transitions to an endemic phase.

Bull case
  • Nirmatrelvir (Paxlovid) is a fully FDA-approved oral antiviral with a well-established safety and efficacy profile for high-risk COVID-19 patients, giving it a durable market position.
  • The patent landscape cleared significantly when the Federal Circuit affirmed invalidation of Enanta's competing patent in June 2026, removing a litigation overhang for Pfizer.
  • Real-world evidence from over 700,000 patients continues to support hospitalization and mortality reduction, and the drug remains a key tool for high-risk populations.
Bear case
  • Paxlovid sales are declining sharply as COVID-19 transitions to endemic status: Pfizer guided 2026 Paxlovid/Comirnaty combined revenue of roughly $4-5 billion, down from prior years, with Q1 2026 Paxlovid revenue of just $186 million (down 62% YoY).
  • The drug faces ongoing competition from other COVID-19 treatments and vaccines, and demand is highly seasonal and unpredictable.
  • Viral rebound after Paxlovid treatment remains a clinical concern that could limit broader adoption.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the US since 2004 (Octagam 5%) and 2014/2015/2021 (Octagam 10% for various indications).

Octagam immune globulin intravenous (human) Updated Nov 4

What to watch

Octagam is an already-approved, marketed IVIg product with no pending FDA decision or pivotal readout. For Pfizer investors, this drug is immaterial to the stock thesis; watch the broader IVIg market for pricing and supply dynamics, but Octagam alone will not move PFE shares.

Bull case
  • Octagam is FDA-approved for three distinct indications: primary humoral immunodeficiency (since 2004), chronic ITP (since 2015), and adult dermatomyositis (since 2021, with 7-year orphan drug exclusivity through 2028).
  • As an IVIg product, Octagam benefits from steady demand driven by patients with chronic immune deficiencies who require regular infusions.
  • Pfizer's US marketing infrastructure and existing relationships with specialty pharmacies and payers provide a stable commercial channel for the product.
Bear case
  • Octagam is a very small product within Pfizer's massive $62-64B annual revenue base and is not broken out as a material product in Pfizer's financial reporting.
  • The IVIg market is highly competitive with at least 11 FDA-approved IVIg products (Gammagard, Privigen, Gamunex-C, Panzyga, etc.), pressuring pricing and market share.
  • Octapharma, the drug's manufacturer, is a privately held Swiss company; Pfizer only holds US marketing rights under a license agreement, limiting Pfizer's strategic control over the asset.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval December 18, 2020).

Orgovyx relugolix Updated Nov 4

What to watch

Orgovyx is an already-approved, commercially mature drug with no upcoming FDA decision or pivotal readout. For Pfizer investors, the drug's sales trajectory matters only at the margins of a $63B+ revenue base. The next notable event is whether Orgovyx crosses the $1 billion annual sales threshold, which would trigger a $325 million milestone payment from Pfizer to Sumitomo (already factored into Sumitomo's guidance). Watch Sumitomo Pharma's quarterly reports for Orgovyx sales trends and any label expansion efforts.

Bull case
  • First and only oral GnRH antagonist for advanced prostate cancer, offering a convenience advantage over injectable Lupron and other injectable ADT options
  • Strong commercial momentum: Orgovyx sales reached $777 million in North America in the first 9 months of Sumitomo's FY2025 (through Dec 2025), with management calling a $1 billion annual sales milestone 'almost certain to be achieved'
  • Favorable clinical profile: Phase 3 HERO trial showed faster testosterone suppression and lower risk of major adverse cardiovascular events compared to leuprolide
Bear case
  • For Pfizer specifically, Orgovyx is a co-commercialized product with profit-sharing; it is not a top-10 revenue driver and is not separately reported in Pfizer's product revenue tables
  • CE exclusivity for Orgovyx expired in December 2025, exposing it to potential generic competition sooner than the last patent expiry date
  • Injectable GnRH agonists like Lupron remain entrenched standard-of-care with decades of clinical use and established reimbursement
▼ bearish
Impact
PhasePhase 3
Time to marketYears away if at all. The drug is still investigational with no FDA filing. The ongoing Phase 3 SigVie-003 (frontline combination) is still recruiting; even if positive, a regulatory submission would be at least 1-2 years away.

sigvotatug vedotin Updated Nov 4

What to watch

The next catalyst for sigvotatug vedotin is the ongoing Phase 3 SigVie-003 readout (frontline combination with pembrolizumab in PD-L1-high NSCLC), but that trial is still recruiting with no publicly disclosed topline timeline. Pfizer management indicated continued investment in the lung cancer program despite the SigVie-002 miss. Watch for enrollment completion updates or interim analysis announcements from Pfizer.

Bull case
  • A post-hoc analysis of SigVie-002 showed a numerical OS trend in patients receiving sigvotatug vedotin in the second-line setting (one prior therapy), suggesting potential in an earlier treatment context.
  • Pfizer is pressing ahead with the Phase 3 SigVie-003 trial testing sigvotatug vedotin plus pembrolizumab as first-line therapy in PD-L1-high NSCLC, and with other combination studies including a PD-1/VEGF bispecific.
  • IB6 is expressed on approximately 90% of NSCLC tumors and is associated with poor prognosis, making it a broadly relevant target if the right combination or patient selection can be found.
Bear case
  • SigVie-002 (Phase 3, n=703) failed to meet its primary overall survival endpoint versus docetaxel in previously treated non-squamous NSCLC, announced June 22, 2026.
  • Pfizer found no clear relationship between IB6 expression and patient response, undermining the biomarker hypothesis.
  • This was the first Phase 3 readout from the $43 billion Seagen acquisition pipeline, and it was a miss, raising questions about the deal's ADC thesis.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed; first approved in the 1980s.

Sulperazon cefoperazone/sulbactam Updated Nov 4

What to watch

Sulperazon is a mature, off-patent antibiotic with no upcoming regulatory catalysts or clinical readouts. For Pfizer investors, this drug is not a material value driver; the stock's performance will be determined by Pfizer's pipeline (vaccines, oncology, mRNA) and overall revenue trends, not this legacy product.

Bull case
  • Sulperazon remains a trusted antibiotic in many Asian, South American, and European markets where it is still actively prescribed for serious bacterial infections.
  • The global Sulperazon market is projected to grow at a 4-6% CAGR through the mid-2030s, driven by rising bacterial infection rates in emerging markets.
  • Pfizer's established manufacturing and distribution infrastructure for sterile injectables provides a competitive moat for this product in its active markets.
Bear case
  • Sulperazon (cefoperazone) is not available in the US market; the individual component Cefobid was discontinued in the US, limiting the drug's addressable market.
  • As an off-patent, mature antibiotic, Sulperazon faces generic competition in many international markets, pressuring pricing and margins.
  • The global Sulperazon market is estimated at roughly $477-730 million annually, a negligible fraction of Pfizer's $62+ billion total revenue, meaning even a complete loss of the product would barely move Pfizer's stock.
● neutral
Impact
PhasePhase 3
Time to marketPhase 3 trials began enrolling in August 2026 with estimated primary completion dates in 2028-2029. If successful, a BLA submission would follow, with potential FDA approval likely no earlier than 2029-2030.

tilrekimig Updated Nov 4

What to watch

The next hard catalyst for tilrekimig is the topline Phase 3 readout in atopic dermatitis, likely in late 2027 or 2028 given the trials started enrolling in August 2026 with 16-week primary endpoints. No PDUFA date or regulatory filing is expected within the next 12 months. For a Pfizer-sized company, positive Phase 3 data would be a modest positive but not a binary event; watch for enrollment completion updates and any early efficacy signals from the ongoing trials.

Bull case
  • Phase 2 data showed strong efficacy: 47.8% to 62.5% of patients achieved EASI-75 at week 16 across doses versus 9.1% to 19.9% for placebo, meeting the primary endpoint at all doses tested. The drug was well-tolerated with a favorable safety profile.
  • Potential first-in-class trispecific antibody simultaneously blocking three Type 2 inflammation drivers (IL-4, IL-13, and TSLP), which could offer broader efficacy than single-pathway blockers like Dupixent.
  • Once-monthly subcutaneous dosing (37-day half-life) could be a convenience advantage over Dupixent's every-two-week regimen, potentially driving patient and physician adoption.
Bear case
  • Faces entrenched competition from approved biologics: Sanofi/Regeneron's Dupixent (dupilumab, IL-4Rα blocker), Lilly's Ebglyss (lebrikizumab), and LEO Pharma's Adbry (tralokinumab), plus oral JAK inhibitors. Dupixent alone generated over $14 billion in 2025 sales and has a multi-year head start.
  • Phase 3 trials are just beginning (enrollment started August 2026) with primary completion estimates in 2028-2029. The drug is years away from potential approval, and Phase 3 failure risk remains significant despite promising Phase 2 data.
  • As a trispecific antibody, tilrekimig is a novel modality with manufacturing complexity and potential immunogenicity risks that could emerge in larger Phase 3 trials.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed. First approved April 2020; newest indication approved October 7, 2026.

Tukysa tucatinib Updated Nov 3

What to watch

The next catalyst to watch is the European Commission decision on the maintenance indication, following a positive CHMP opinion on October 15, 2026 (typically ratified within 2-3 months). Commercial uptake of the new front-line maintenance indication in both the US and EU will determine whether Tukysa's growth trajectory accelerates from its current modest pace. However, given Tukysa's small contribution to Pfizer's overall revenue, even a meaningful sales inflection is unlikely to materially move PFE shares.

Bull case
  • The October 2026 FDA approval for front-line maintenance expands Tukysa into a much larger patient population (earlier line of therapy), which could meaningfully accelerate sales growth from the current ~$500M annual run rate.
  • HER2CLIMB-05 data showed a >50% improvement in median progression-free survival (24.9 vs 16.3 months), a strong efficacy signal that supports adoption by oncologists.
  • Tukysa's ability to cross the blood-brain barrier gives it a differentiated position for the ~30-50% of HER2+ breast cancer patients who develop brain metastases.
Bear case
  • Tukysa is a small asset within Pfizer's massive portfolio (H1 2026 sales of $234M vs Pfizer's ~$60B annual revenue), so even strong sales growth will have negligible impact on PFE's stock price.
  • The drug faces intense competition from Enhertu (AstraZeneca/Daiichi), a highly effective antibody-drug conjugate that is expanding into earlier lines and HER2-low populations, potentially limiting Tukysa's addressable market.
  • Sales growth has been sluggish (3% in H1 2026, and 9-month 2025 sales were actually down YoY at $344M vs $351M), suggesting the drug was already facing headwinds before the new approval.
▼ bearish
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2012. The drug is in its late-lifecycle phase with broad generic competition now established in the U.S. market.

Xeljanz tofacitinib Updated Nov 4

What to watch

Xeljanz is a declining legacy asset for Pfizer with no upcoming binary catalysts. The key event to watch is the pace of generic erosion in quarterly revenue reports. For Pfizer investors, Xeljanz's decline is already priced into expectations and is a minor factor relative to the company's broader pipeline and non-COVID growth portfolio (oncology, specialty care). The stock's next major catalysts lie elsewhere, such as pipeline readouts for berobenatide and other novel assets.

Bull case
  • Xeljanz remains a recognized brand with established physician prescribing patterns across multiple autoimmune indications, providing a base of ongoing revenue.
  • Pfizer's overall Q3 2026 earnings beat estimates and the company raised full-year guidance, showing the broader business can absorb Xeljanz's decline.
  • Xeljanz was removed from Medicare price negotiation for 2029 onward due to generic availability, removing a potential pricing overhang.
Bear case
  • Multiple AB-rated generic versions of Xeljanz and Xeljanz XR launched in the U.S. starting June 2026, with discounts reportedly reaching 90%+ below brand pricing, driving rapid revenue erosion.
  • Xeljanz revenue was roughly $251 million in 2026, down 22% year-over-year, and the global market for tofacitinib is forecast to shrink from ~$1.47B in 2026 to ~$835M by 2035 (negative CAGR).
  • The drug carries a boxed FDA warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, limiting its addressable patient population.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the EU (since June 2016) and multiple ex-US countries. Pediatric use from birth was authorized by the EMA following a CHMP positive opinion in September 2024.

Zavicefta ceftazidime/avibactam Updated Nov 4

What to watch

Zavicefta is a mature, marketed product with no upcoming binary catalyst. Watch for generic/biosimilar erosion timelines in ex-US markets and any new resistance data that could shift usage patterns, but neither is likely to move Pfizer's stock given the drug's small revenue contribution.

Bull case
  • Zavicefta is on the WHO Model List of Essential Medicines (RESERVE group), ensuring ongoing global demand as a last-resort antibiotic for carbapenem-resistant infections.
  • EMA has approved pediatric use from birth, expanding the addressable patient population.
  • The global ceftazidime-avibactam market was estimated at roughly $0.93B in 2025 and is projected to grow at a 4.5-8% CAGR through the early 2030s, driven by rising antimicrobial resistance.
Bear case
  • Zavicefta faces competition from other novel beta-lactamase inhibitor combinations (e.g. meropenem-vaborbactam, imipenem-cilastatin-relebactam) that could erode market share.
  • Emerging resistance to ceftazidime-avibactam itself is a documented risk that could limit future use.
  • The drug is a very small part of Pfizer's $62.6B total revenue (2025), so even a major sales swing would barely move PFE shares.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1991. Pfizer is discontinuing its branded formulations; generic equivalents are widely available.

Zithromax azithromycin Updated Nov 4

What to watch

Zithromax is a legacy off-patent drug with no upcoming binary catalysts. Pfizer is actively discontinuing its branded Zithromax formulations (injection discontinued Jan 2026, tablets to be discontinued as of Nov 2026). The drug is a negligible revenue contributor to Pfizer's $63.6B annual revenue and will not drive the stock. Investors should focus on Pfizer's growth drivers (new launches, acquired products) rather than this fading legacy brand.

Bull case
  • Zithromax (azithromycin) remains a widely prescribed, FDA-approved antibiotic for respiratory, skin, and sexually transmitted infections, with a well-established safety and efficacy profile.
  • The FDA approved a supplemental label expansion in July 2026 for pediatric community-acquired pneumonia (ages 6 months+), potentially extending the drug's utility in a niche pediatric segment.
  • The global azithromycin market is estimated at roughly $7-8 billion annually and is projected to grow at a 5-6% CAGR through 2031, driven by demand in emerging markets.
Bear case
  • Pfizer is actively discontinuing its branded Zithromax products: injection discontinued January 2026, oral suspension 1g packets discontinued July 2025, and tablets (250mg, 500mg) listed as 'To Be Discontinued' as of April/November 2026.
  • Zithromax patents expired in 2005, and the market is dominated by generics from over 22 other manufacturers, compressing margins and limiting Pfizer's branded sales.
  • The FDA approved a label update in July 2026 adding a warning about cardiovascular death risk, which could further dampen demand.

Other drugs in filings and trials

no drug report yet
  • VELSIPITY Last: Approval · Oct 12, 2023
  • NGENLA Last: Approval · Jun 27, 2023
  • ZAVZPRET Last: Approval · Mar 9, 2023
  • BENDAMUSTINE HYDROCHLORIDE Last: Approval · Dec 15, 2022
  • PEMETREXED DISODIUM Last: Approval · Jun 22, 2022
  • PEMETREXED DITROMETHAMINE Last: Approval · Jun 10, 2022
  • BORTEZOMIB Last: Approval · May 2, 2022
  • TIVDAK Last: Approval · Sep 20, 2021
  • DAPTOMYCIN Last: Approval · Jun 21, 2021
  • NYVEPRIA Last: Approval · Jun 10, 2020
  • ABRILADA Last: Approval · Nov 15, 2019
  • EPINEPHRINE Last: Approval · Nov 5, 2019
  • RUXIENCE Last: Approval · Jul 23, 2019
  • ZIRABEV Last: Approval · Jun 27, 2019
  • TRAZIMERA Last: Approval · Mar 11, 2019
  • DAURISMO Last: Approval · Nov 21, 2018
  • VIZIMPRO Last: Approval · Sep 27, 2018
  • DOXERCALCIFEROL Last: Approval · Jul 24, 2018
  • NIVESTYM Last: Approval · Jul 20, 2018
  • RETACRIT Last: Approval · May 15, 2018
  • IXIFI Last: Approval · Dec 13, 2017
  • TROXYCA ER Last: Approval · Aug 19, 2016
  • ZOLEDRONIC ACID Last: Approval · Dec 28, 2015
  • LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Last: Approval · Jun 18, 2015
  • PARICALCITOL Last: Approval · Oct 21, 2014
  • 2.5% Diclofenac Patches 1 trial
  • Bupivacaine 1 trial
  • Digoxin 1 trial
  • disitamab vedotin 1 trial
  • Folic Acid 1 trial
  • HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin 1 trial
  • Ketamine 1 trial
  • Ketamine only 1 trial
  • Lidocaine cream and general advice 1 trial
  • PF-06835375 1 trial
  • PF-06838435 (formerly SPK-9001) 1 trial
  • PF-07868489 2 trials

Past FDA events & how the stock moved

40 events
DateDrugEvent1 day5 days
Aug 17, 2026PadcevPDUFA decision+1.7%+4.4%
Oct 11, 2024HympavziApproval−0.9%−0.4%
Mar 7, 2024TalzennaApproval+0.1%+3.5%
Oct 12, 2023VELSIPITYApproval−3.0%−5.8%
Aug 14, 2023ElrexfioApproval−1.8%+2.7%
Jun 27, 2023NGENLAApproval−1.6%−1.2%
Jun 23, 2023LitfuloApproval−4.8%−5.3%
May 25, 2023nirmatrelvirApproval−2.7%−0.7%
Mar 9, 2023ZAVZPRETApproval−1.8%+0.6%
Dec 15, 2022BENDAMUSTINE HYDROCHLORIDEApproval−5.7%−5.2%
Jun 22, 2022PEMETREXED DISODIUMApproval+4.1%+5.9%
Jun 10, 2022PEMETREXED DITROMETHAMINEApproval−7.5%−10.1%
May 2, 2022BORTEZOMIBApproval+0.5%−0.9%
Jan 14, 2022CibinqoApproval−2.6%−7.2%
Sep 20, 2021TIVDAKApproval+0.1%−0.7%
Jun 21, 2021DAPTOMYCINApproval+2.1%+0.8%
Sep 25, 2020XeljanzApproval+1.8%+1.7%
Jun 10, 2020NYVEPRIAApproval−8.0%−7.3%
Apr 17, 2020TukysaApproval+0.6%+4.2%
Feb 27, 2020NurtecApproval−3.7%+2.1%
Nov 15, 2019ABRILADAApproval+1.8%+4.9%
Nov 5, 2019EPINEPHRINEApproval−1.1%−1.9%
Nov 1, 2019IbranceApproval−0.9%−2.5%
Jul 23, 2019RUXIENCEApproval+0.2%−9.4%
Jun 27, 2019ZIRABEVApproval+0.8%+2.2%
Mar 11, 2019TRAZIMERAApproval+2.0%+2.3%
Nov 21, 2018DAURISMOApproval−0.9%+4.5%
Nov 2, 2018LorbrenaApproval−0.3%+2.2%
Oct 16, 2018TalzennaApproval+3.4%+2.3%
Sep 27, 2018VIZIMPROApproval+0.9%+2.3%
Jul 24, 2018DOXERCALCIFEROLApproval+2.1%+7.3%
Jul 20, 2018NIVESTYMApproval−0.4%+2.8%
May 15, 2018RETACRITApproval−0.5%−0.4%
Dec 13, 2017IXIFIApproval−0.3%−0.3%
Aug 19, 2016TROXYCA ERApproval−1.0%−1.1%
Feb 23, 2016XeljanzApproval−0.1%−0.0%
Dec 28, 2015ZOLEDRONIC ACIDApproval+0.6%−1.4%
Jun 18, 2015LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERApproval+1.0%−0.2%
Feb 3, 2015IbranceApproval+2.2%+8.8%
Oct 21, 2014PARICALCITOLApproval+1.3%+4.2%

Clinical trials

39 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
disitamab vedotinDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Phase 3Active not recruiting412Jan 29, 2027
AbrysvoStudy to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Phase 3Active not recruiting38,861Jan 18, 2027
TalzennaContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPhase 3Active not recruiting77Dec 31, 2026
PF-07104091 monotherapy dose escalationPF-07104091 as a Single Agent and in Combination TherapyPhase 2Active not recruiting157Dec 31, 2026
Vepdegestrant (ARV-471/PF-07850327)Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPhase 3Active not recruiting59Dec 30, 2026
XtandiA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Phase 3Active not recruiting600Dec 28, 2026
LitfuloA 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.Phase 2Active not recruiting128Dec 8, 2026
Ritlecitinib higher doseA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataPhase 3Active not recruiting208Dec 2, 2026
PF-07868489A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489Phase 2Terminated42Oct 9, 2026
ARV-471TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)Phase 2Terminated20Oct 6, 2026
MET233 and MET097A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesPhase 2Completed201Sep 29, 2026
PF-06835375Safety and Efficacy Study of PF-06835375 in Primary Immune ThrombocytopeniaPhase 2Terminated61Sep 23, 2026
Folic AcidFolic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted TherapyPhase 2Completed84Sep 22, 2026
vepdegestrantTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)Phase 2Terminated11Sep 10, 2026
ARV-471TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Phase 2Active not recruiting37Sep 1, 2026
AbrysvoA Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.Phase 3Completed130Aug 25, 2026
PF-07220060 + PF-07104091 combination dose escalationA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsPhase 2Active not recruiting192Aug 23, 2026
OxaliplatinXELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)Phase 3Completed1,024Aug 15, 2026
DoxorubicinIxazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerPhase 2Completed30Aug 4, 2026
PF-07868489A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionPhase 2Completed97Jul 31, 2026
PF-06838435 (formerly SPK-9001)Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BPhase 2Terminated21Jul 23, 2026
HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatinD2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric CarcinomaPhase 3Completed367Jun 30, 2026
2.5% Diclofenac PatchesSustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to OsteoarthritisPhase 2Completed307Jun 26, 2026
Ketamine onlyEvaluating the Neuromodulatory Effect of Ketamine in Long COVID-19Phase 2Completed20Jun 22, 2026
BupivacaineA Study of Stellate Ganglion Block for Prevention of Atrial FibrillationPhase 3Completed200Jun 8, 2026
BraftoviA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerPhase 2Active not recruiting107Jun 1, 2026
CarboplatinDocetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus CancerPhase 2Terminated · results31Jun 1, 2026
disitamab vedotinA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Phase 2Active not recruiting120May 31, 2026
Lidocaine cream and general advicePulsed Electromagnetic Field on Chronic Anal Fissure HealingPhase 3Completed100May 22, 2026
AK112A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerPhase 2Active not recruiting254May 15, 2026
Multivalent Pneumococcal Vaccine - Formulation 1A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsPhase 2Completed1,710May 12, 2026
XeljanzTherapies for Down Syndrome Regression DisorderPhase 2Completed66May 5, 2026
KetamineKetamine-Assisted Recovery for Methamphetamine Use Disorder & HIVPhase 2Completed17May 5, 2026
DigoxinTrial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)Phase 2Completed41Apr 13, 2026
LitfuloDouble Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in RemissionPhase 2Completed62Apr 9, 2026
CarboplatinNadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.Phase 2Completed117Apr 9, 2026
maplirpacept (PF-07901801)A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.Phase 2Terminated40Apr 9, 2026
Tisotumab VedotinSafety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerPhase 2Terminated214Mar 19, 2026
0.5% Bupivacaine HClThe Anesthetic and Analgesic Effect of Adjunct Liposomal Bupivacaine in Periodontal Surgical ProceduresPhase 2Completed58Mar 15, 2026

1 newer trial for subscribers. See plans